Non-Inferiority Analysis of Adjuvant Radiation versus Observation Post-Radical Prostatectomy

Huang Wei Su BS, **Linda M. Huynh MSc, Thomas Ahlering MD
Introduction and Methods

• Adjuvant radiation is recommended to **30-40%** of post-RP patients based on pathology.

• At our center, we do not routinely recommend ART post-RP.

• Non-inferiority analysis of PCSM/OM and cost-savings at a median follow-up of 5.6 years
Conclusions

291 NED Patients

$37,000 Medicare expense

= $10 million in ART costs

<table>
<thead>
<tr>
<th>Matched Cohorts</th>
<th>UCI Cohort</th>
<th>SWOG</th>
<th>EORTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-year Disease-Specific Survival</td>
<td>98.5%</td>
<td>na</td>
<td>97.7%</td>
</tr>
<tr>
<td>5-year Overall Survival</td>
<td>92%</td>
<td>91%</td>
<td>92%</td>
</tr>
</tbody>
</table>

1. 50% of patients recommended ART did not recur.
2. Salvage HT yielded non-inferior cancer control.
3. ART should be weighed against significant cost, lack of mortality benefit and detriment to quality of life.